Besifovir Dipivoxil Maleate Effective, Safe for Long-Term Treatment of Chronic Hepatitis B
Study data supports the long-term efficacy and safety of besifovir dipivoxil maleate (BSV) for the treatment of chronic hepatitis B (CHB).
Study data supports the long-term efficacy and safety of besifovir dipivoxil maleate (BSV) for the treatment of chronic hepatitis B (CHB).
The U.S. Preventive Services Task Force (USPSTF) recommends screening adolescents and adults at increased risk for hepatitis B virus (HBV) infection.
Hepatitis B virus prevalence was 7 to 10 times higher in a homeless population of Los Angeles compared to the general population of the United States.
A study identifies risk factors for hepatocellular carcinoma (HCC) after the first 5 years of receiving antiviral therapy in white patients with chronic hepatitis B.
Front-line providers minimally could check HBV DNA and ALT during pregnancy to assess mother‐to‐child transmission risk but HBeAg is recommended to be included in the initial HBV evaluation to get a more comprehensive understanding of the patient’s HBV disease state.
Because after hepatitis B viral suppression the cause and intervention for elevated alanine aminotransferase is somewhat unknown, investigators conducted a real-world study.
Researchers of studies on the effect of conflict-driven migration on rates of hepatitis indicate that mass migration from high-burden countries has significantly increased the prevalence of both hepatitis C virus (HCV) and hepatitis B virus (HBV) infection in the host nation.
Patients with hepatitis C virus (HCV) and comorbidities, including hepatocellular carcinoma (HCC), clinically significant portal hypertension, and cirrhosis were shown to have significantly higher survival rates when treatment included directly acting antiviral agent (DAA) therapy, according to the results of several studies presented at the American Association for the Study of Liver Diseases’ The Liver…
New diagnostic tools used to identify hepatitis C virus (HCV) and hepatitis B virus (HBV) utilize simple questionnaires and emergency medical records (EMR) to alert physicians in both primary care and high-volume care settings about patients at risk for viral hepatitis infection or reactivation. The results of these studies were presented at the American Association…
Pegylated-interferon (PEG-IFN) added to nucleos(t)ide analog (NA) treatment may be associated with hepatitis B surface antigen (HbsAg) decline and once HbsAg-seroclearance is achieved, discontinuation of NA is not associated with a higher risk for HbsAg-reversion.